Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects-Reference-Cited by-同舟云学术

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

Published:2018-10-16 Issue:10 Volume:13 Page:e0204974
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

McClure Matthew W.,Berliba Elina,Tsertsvadze Tengiz,Streinu-Cercel Adrian,Vijgen Leen,Astruc Béatrice,Patat Alain,Westland Christopher,Chanda Sushmita,Zhang Qingling,Kakuda Thomas N.,Vuong Jennifer,Khorlin Nick,Beigelman Leonid,Blatt Lawrence M.,Fry John^ORCID

Funder

Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference19 articles.

1. World Health Organization. Hepatitis C–Fact Sheet 164. 2017. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/

2. EASL recommendations on treatment of hepatitis C 2016;J Hepatol,2017

3. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing and treating hepatitis C. 2017. Available from: https://www.hcvguidelines.org/

4. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis;CS Bang;BMC Gastroenterol,2017

5. Global epidemiology and burden of HCV infection and HCV-related disease;AP Thrift;Nat Rev Gastroenterol Hepatol,2017

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-Ascending-Dose, Food-Effect, and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Pangenotypic Anti-Hepatitis C Virus Drug Holybuvir in Healthy Chinese Subjects;Antimicrobial Agents and Chemotherapy;2023-02-21

2. 4′-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives;Accounts of Chemical Research;2022-01-25

3. Curing Hepatitis C with Direct‐Acting Antiviral Therapy;New Drug Development for Known and Emerging Viruses;2021-12-03

4. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic;European Journal of Medicinal Chemistry;2021-03

5. Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections;ChemMedChem;2021-02-12